Results 1 to 10 of about 908,554 (203)

NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects [PDF]

Diagnostics, 2021
Tropomyosin receptor kinase (TK) is encoded by the neurotrophic tyrosine receptor kinase genes (NTRK) 1, 2, and 3, whose activation plays an important role in cell cycle proliferation and survival.
Vasiliki Siozopoulou, Evelien Smits, Koen De Winne, Elly Marcq, Patrick Pauwels   +4 more
doaj   +7 more sources

Detection of NTRK Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort [PDF]

Diagnostics, 2022
Gene fusions involving NTRK1, NTRK2, and NTRK3 are rare drivers of cancer that can be targeted with histology-agnostic inhibitors. This study aimed to determine the nationwide landscape of NTRK/TRK testing in the Netherlands and the usage of pan-TRK ...
Bart Koopman, Chantal C. H. J. Kuijpers, Harry J. M. Groen, Wim Timens, Ed Schuuring, Stefan M. Willems, Léon C. van Kempen   +6 more
doaj   +6 more sources

Molecular and clinicopathologic features of gliomas harboring NTRK fusions [PDF]

Acta Neuropathologica Communications, 2020
Fusions involving neurotrophic tyrosine receptor kinase (NTRK) genes are detected in ≤2% of gliomas and can promote gliomagenesis. The remarkable therapeutic efficacy of TRK inhibitors, which are among the first Food and Drug Administration-approved ...
Matthew Torre, Varshini Vasudevaraja, Jonathan Serrano, Michael DeLorenzo, Seth Malinowski, Anne-Florence Blandin, Melanie Pages, Azra H. Ligon, Fei Dong, David M. Meredith, MacLean P. Nasrallah, Craig Horbinski, Sonika Dahiya, Keith L. Ligon, Mariarita Santi, Shakti H. Ramkissoon, Mariella G. Filbin, Matija Snuderl, Sanda Alexandrescu   +18 more
doaj   +7 more sources

Detection of NTRK fusions by RNA-based nCounter is a feasible diagnostic methodology in a real-world scenario for non-small cell lung cancer assessment [PDF]

Scientific Reports, 2023
NTRK1, 2, and 3 fusions are important therapeutic targets for NSCLC patients, but their prevalence in South American admixed populations needs to be better explored.
Rodrigo de Oliveira Cavagna, Edilene Santos de Andrade, Monise Tadin Reis, Flávia Escremim de Paula, Gustavo Noriz Berardinelli, Murilo Bonatelli, Gustavo Ramos Teixeira, Beatriz Garbe Zaniolo, Josiane Mourão Dias, Flávio Augusto Ferreira da Silva, Carlos Eduardo Baston Silva, Marina Xavier Reis, Erika Lopes Maia, Thainara Santos de Alencar, Alexandre Arthur Jacinto, Rachid Eduardo Noleto da Nóbrega Oliveira, Miguel A. Molina-Vila, Letícia Ferro Leal, Rui Manuel Reis   +18 more
doaj   +3 more sources

Phase separation underlies signaling activation of oncogenic NTRK fusions. [PDF]

Proc Natl Acad Sci U S A, 2023
Significance NTRK (neurotrophic tyrosine receptor kinase) gene fusions with various N-terminal partners are the major forms of oncogenic TRK (tropomyosin receptor kinases) activation.
Zhu T, Xie J, He H, Li H, Tang X, Wang S, Li Z, Tian Y, Li L, Zhu J, Zhu G.   +10 more
europepmc   +4 more sources

RNA hybrid-capture next-generation sequencing has high sensitivity in identifying known and less characterized oncogenic and likely oncogenic NTRK fusions in a real-world standard-of-care setting [PDF]

Frontiers in Genetics
IntroductionNTRK1, NTRK2, and NTRK3 gene fusions are rare oncogenic driver alterations found in diverse tumor types of adults and children. They are clinically important biomarkers as tumors harboring these genomic alterations have high response rates to
Zachary D. Wallen, Marni Tierno, Erica Schnettler, Alison Roos, Michelle Green, Kobina Amoah, Rebecca A. Previs, Stephanie Hastings, Sarabjot Pabla, Taylor J. Jensen, Brian Caveney, Marcia Eisenberg, Pratheesh Sathyan, Shakti H. Ramkissoon, Shakti H. Ramkissoon, Eric A. Severson   +15 more
doaj   +3 more sources

NTRK Fusions in 1113 Solid Tumors in a Single Institution [PDF]

Diagnostics, 2022
Most NTRK fusions occur at very low frequencies in various common cancers. Recent recommendations on NTRK testing recommend immunohistochemistry (IHC) as the initial test for tumor types with a low frequency of NTRK fusions.
Heejin Bang, Mi-Sook Lee, Minjung Sung, Juyoung Choi, Sungbin An, Seok-Hyung Kim, Seung Eun Lee, Yoon-La Choi   +7 more
doaj   +3 more sources

NTRK Fusions in a Sarcomas Series: Pathology, Molecular and Clinical Aspects [PDF]

Pathology and Oncology Research, 2022
Targeting molecular alterations has been proven to be an inflecting point in tumor treatment. Especially in recent years, inhibitors that target the tyrosine receptor kinase show excellent response rates and durable effects in all kind of tumors that ...
Vasiliki Siozopoulou, Vasiliki Siozopoulou, Elly Marcq, Koen De Winne, Koen Norga, Gertjan Schmitz, Valerie Duwel, Philippe Delvenne, Evelien Smits, Evelien Smits, Patrick Pauwels, Patrick Pauwels   +11 more
doaj   +3 more sources

NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target. [PDF]

Int J Mol Sci, 2020
The neurotrophic tropomyosin receptor kinase (NTRK) genes (NTRK1, NTRK2, and NTRK3) code for three transmembrane high-affinity tyrosine-kinase receptors for nerve growth factors (TRK-A, TRK-B, and TRK-C) which are mainly involved in nervous system ...
Gambella A, Senetta R, Collemi G, Vallero SG, Monticelli M, Cofano F, Zeppa P, Garbossa D, Pellerino A, Rudà R, Soffietti R, Fagioli F, Papotti M, Cassoni P, Bertero L.   +14 more
europepmc   +4 more sources

Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project [PDF]

Cancer Treatment and Research Communications, 2022
Introduction: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers in various tumor types. Limited data exist on the overall survival (OS) of patients with tumors with NTRK gene fusions and on the co-occurrence of NTRK fusions ...
John Bridgewater, Xiaolong Jiao, Mounika Parimi, Clare Flach, Jeran Stratford, Atanas Kamburov, Arndt A. Schmitz, Jihong Zong, John A. Reeves, Karen Keating, Amanda Bruno, Marc Fellous, Mariana Buongermino Pereira, Lyudmila Bazhenova   +13 more
doaj   +3 more sources